Glucocorticosteroids enhance replication of respiratory viruses: Effect of adjuvant interferon

Scientific Reports

Volumn 2014, Issue , 2014, Pages

  Thomas, Belinda J ^a,b,c   Porritt, Rebecca A ^b,c   Hertzog, Paul J ^b,c   Bardin, Philip G ^a,b,c   Tate, Michelle D ^b,c  

^a MONASH MEDICAL CENTRE   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOKINE; GLUCOCORTICOID; IMMUNOLOGICAL ADJUVANT; INTERFERON;

ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; FEMALE; HUMAN; INFLUENZA A VIRUS; INNATE IMMUNITY; LUNG; METABOLISM; MOUSE; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; RHINOVIRUS; SEVERITY OF ILLNESS INDEX; VETERINARY; VIROLOGY; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOKINES; EPITHELIAL CELLS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNITY, INNATE; INFLUENZA A VIRUS; INTERFERONS; LUNG; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; RHINOVIRUS; SEVERITY OF ILLNESS INDEX; VIRUS REPLICATION;

EID: 84925263127     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07176     Document Type: Article

References (46)

1. Dulek, D. E. & Peebles, R. S., Jr. Viruses and asthma. Biochim. Biophys. Acta. 1810, 1080-1090 (2011).
2. Singanayagam, A., Joshi, P. V., Mallia, P. & Johnston, S. L. Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Med. 10, 27 (2012).
3. Bergman, H., Livornese, L. L., Jr., Sambhara, S., Santoro, J. & Dessain, S. K. Patients Hospitalized with pH1N1 Influenza in an Academic Community Medical Center. Open Respir Med J. 5, 19-23 (2011).
4. Zarogoulidis, P. et al. Long-term respiratory follow-up of H1N1 infection. Virol J. 8, 319 (2011).
5. Nannini, L. J., Poole, P., Milan, S. J., Holmes, R. & Normansell, R. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 11, CD003794 (2013).
6. White, P., Thornton, H., Pinnock, H., Georgopoulou, S. & Booth, H. P. Overtreatment of COPD with Inhaled Corticosteroids - Implications for Safety and Costs: Cross-Sectional Observational Study. PLoS One. 8, e75221 (2013).
7. McKeever, T., Harrison, T. W., Hubbard, R. & Shaw, D. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest. 144, 1788-1794 (2013).
8. Suissa, S., Patenaude, V., Lapi, F. & Ernst, P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 68, 1029-1036 (2013).
9. Ducharme, F. M. et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N. Engl. J. Med. 360, 339-353 (2009).
10. Price, D., Yawn, B., Brusselle, G. & Rossi, A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 22, 92-100 (2013).
11. Puhakka, T. et al. The common cold: effects of intranasal fluticasone propionate treatment. J. Allergy Clin. Immunol. 101, 726-731 (1998).
12. Gustafson, L. M., Proud, D., Hendley, J. O., Hayden, F. G. & Gwaltney, J. M., Jr. Oral prednisone therapy in experimental rhinovirus infections. J. Allergy Clin. Immunol. 97, 1009-1014 (1996).
13. Skevaki, C. L. et al. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. Clin. Exp. Allergy. 39, 1700-1710 (2009).
14. Edwards, M. R., Haas, J., Panettieri, R. A., Jr., Johnson, M. & Johnston, S. L. Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements. J. Biol. Chem. 282, 15366-15375 (2007).
15. Van Ly, D. et al. Effects of beta(2) Agonists, Corticosteroids, and Novel Therapies on Rhinovirus-Induced Cytokine Release and Rhinovirus Replication in Primary Airway Fibroblasts. J Allergy (Cairo). 2011, 457169 (2011).
16. Davies, J. M. et al. Budesonide and formoterol reduce early innate anti-viral immune responses in vitro. PLoS One. 6, e27898 (2011).
17. Edwards, M. R., Johnson, M. W. & Johnston, S. L. Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 34, 616-624 (2006).
18. Bochkov, Y. A. et al. Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses. Resp Res. 14, 98 (2013).
19. Wang, J. et al. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection. J. Immunol. 182, 1296-1304 (2009).
20. Schoggins, J. W. & Rice, C. M. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 1, 519-525 (2011).
21. Thomas, B. J. et al. Transforming growth factor-beta enhances rhinovirus infection by diminishing early innate responses. Am. J. Respir. Cell Mol. Biol. 41, 339-347 (2009).
22. Tate, M. D., Schilter, H. C., Brooks, A. G. & Reading, P. C. Responses of mouse airway epithelial cells and alveolar macrophages to virulent and avirulent strains of influenza A virus. Viral Immunol. 24, 77-88 (2011).
23. Tate, M. D., Pickett, D. L., van Rooijen, N., Brooks, A. G. & Reading, P. C. Critical role of airway macrophages in modulating disease severity during influenza virus infection of mice. J. Virol. 84, 7569-7580 (2010).
24. Gern, J. E. et al. Rhinovirus enters but does not replicate inside monocytes and airway macrophages. J. Immunol. 156, 621-627 (1996).
25. Wark, P. A. et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J. Exp. Med. 201, 937-947 (2005).
26. Witte, K. et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 10, 702-714 (2009).
27. Singam, R. et al. Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice. Virol J. 3, 32 (2006).
28. Chu, H. W., Campbell, J. A., Rino, J. G., Harbeck, R. J. & Martin, R. J. Inhaled fluticasone propionate reduces concentration of Mycoplasma pneumoniae, inflammation, and bronchial hyperresponsiveness in lungs of mice. J. Infect. Dis. 189, 1119-1127 (2004).
29. Suzuki, T. et al. Effects of dexamethasone on rhinovirus infection in cultured human tracheal epithelial cells. AmJ Physiol Lung Cell Mol Physiol. 278, L560-571 (2000).
30. Miller, E. K. et al. A mechanistic role for type III IFN-lambda1 in asthma exacerbations mediated by human rhinoviruses. Am. J. Respir. Crit. Care Med. 185, 508-516 (2012).
31. Schwantes, E. A. et al. Interferon gene expression in sputum cells correlates with the Asthma Index Score during virus-induced exacerbations. Clin. Exp. Allergy. 44, 813-821 (2014).
32. O'Byrne, P. M. et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 183, 589-595 (2011).
33. Reddel, H. K. et al. Effect of different asthma treatments on risk of cold-related exacerbations. Eur. Respir. J. 38, 584-593 (2011).
34. Contoli, M. et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat. Med. 12, 1023-1026 (2006).
35. Edwards, M. R. et al. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. Mucosal Immunol. 6, 797-806 (2013).
36. Mallia, P. et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am. J. Respir. Crit. Care Med. 183, 734-742 (2011).
37. Sykes, A. et al. TLR3, TLR4 and TLRs7-9 Induced Interferons AreNot Impaired in Airway and Blood Cells in Well Controlled Asthma. PLoS One. 8, e65921 (2013).
38. Sykes, A. et al. Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax. 69, 240-246 (2014).
39. Bochkov, Y. A. et al. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol. 3, 69-80 (2010).
40. McCullers, J. A. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol. 12, 252-262 (2014).
41. Molyneaux, P. L. et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 188, 1224-1231 (2013).
42. Grunberg, K. et al. Rhinovirus-induced airway inflammation in asthma: effect of treatment with inhaled corticosteroids before and during experimental infection. Am. J. Respir. Crit. Care Med. 164, 1816-1822 (2001).
43. de Kluijver, J. et al. Interleukin-1beta and interleukin-1ra levels in nasal lavages during experimental rhinovirus infection in asthmatic and non-asthmatic subjects. Clin. Exp. Allergy. 33, 1415-1418 (2003).
44. Djukanovic, R. et al. The Effect of Inhaled IFN-beta on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial. Am. J. Respir. Crit. Care Med. 190, 145-154 (2014).
45. Levy, D. E., Marie, I. J. & Durbin, J. E. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol. 1, 476-486 (2011).
46. Donnelly, R. P., Dickensheets, H. & O'Brien, T. R. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol. 32, 443-450 (2011).